ARCA biopharma, Inc. (NASDAQ:ABIO) was founded in 2001 and is headquartered in Westminster, Colorado, USA, with 20 full-time employees. It is a biopharmaceutical company that develops gene-targeted drugs and treatments. Heart failure and cardiovascular disease.
ARCA biopharma (ABIO):
ARCA biopharma is a biopharmaceutical company dedicated to the development of gene-targeted therapies for cardiovascular diseases.
Ark’s main product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, currently in clinical trials for the treatment of heart failure and left ventricular insufficiency.
In addition, Ark Biology is also involved in the formulation of preclinical plans for AB171, a new chemical agent used to treat various cardiovascular indications such as peripheral arterial disease and chronic heart failure.
Ark biotech companies and Medtronic (Medtronic, Inc.) signed a cooperation agreement to support GENETIC-AF 2B clinical trials; and US Laboratories (Laboratory Corporation of America) together to provide complete diagnostic testing and services to Support GENETIC-AF test.